Pharmacokinetic study of the variability of indinavir drug levels when boosted withritonavir in HIV-infected Children

CURRAS V, HÖCHT C, MANGANO A, NISELMAN V, MARIÑO-HERNANDEZ E, CÁCERES GUIDO P, MECIKOVSKY D, BELLUSCI C, BOLOGNA R, SEN L, RUBIO MC,BRAMUGLIA GF,

PHARMACOLOGY.

S. Karger AG

Lugar: Basilea- Suiza; Año: 2009 vol. 83 p. 59 - 66

0031-7012

The aim of this work is to: (1) assess therapeutic drug monitoring of indinavir (IDV) during clinical routine practice in HIV-infected children, whose antiretroviral treatment includes IDV boosted with ritonavir (RTV), and (2) describe a possible relationship between IDV pharmacokinetics and MDR1 genotypes. In 21 ambulatory pediatric patients receiving IDV plus RTV, IDV plasma levels and MDR1 genotypes on exon 26 (C3435T) were determined. Nine of the 21 patients initially receiving 250 mg/m(2) IDV yielded trough levels below 0.10 mug/ml (median: 0.21, range: 0.04-1.31 mug/ml). When the dosage was increased to 400 mg/m(2) IDV plus 100 mg/m(2) RTV b.i.d., all, except 1 patient, achieved levels above 0.10 mug/ml. Pharmacokinetic analysis showed higher volume of distribution median values related to the C/C genotype in comparison with C/T or T/T genotypes for exon 26 (4.57 vs. 1.20 and 1.50 l/kg, respectively; p = 0.002). Although a higher median value of clearance was observed with the C/C genotype, the difference was not statistically significant (1.43 vs. 0.27 and 0.42 l/h, respectively; p = 0.052). These results may be explained by a reduced absorption of the drug, related with lower plasma IDV levels in patients carrying the C/C genotype in exon 26.